by Patrick R. Coyle | Sep 1, 2026 | Patient Access
A specialty product with acceptable coverage, underperforming its forecast, and a working explanation that was wrong. Every function’s data looked healthy on its own. Integrated across enrollment, coverage, affordability and dispensing, approvals were not...
by Patrick R. Coyle | Sep 1, 2026 | Patient Access
A label narrower than the trial that supported it, and the question no forecast model asks. When approval defines the market as refractory patients rather than diagnosed ones, the commercial problem stops being demand conversion and becomes patient identification. A...
